BioSpace News Archive

MedX Health Corp., a global leader in teledermatology, is pleased to announce that on October 21, 2022 it finalized Closing of the private placement of Series III Convertible Loan Notes which, since it was first announced, has comprised issuance of a total of 22 Series III Notes, to raise a total of $1.1 Million.

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced results from its Phase 3 SPOTLIGHT trial that evaluated the impact of various clinical factors, including baseline Prostate Specific Antigen (PSA) levels, PSA doubling time and Gleason score, on detection rates (DRs) for 18F-rhPSMA-7.3 in recurrent prostate cancer.